Business Context and Reporting Period
Company: Canopy Growth Corp (CGC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2025
Reporting Currency: Canadian Dollars (CDN$)
Canopy Growth is a global cannabis company operating primarily in Canada, Europe, and Australia, with a significant non-controlling interest in Canopy USA, LLC, which holds U.S. cannabis investments. The company reports two segments: Cannabis and Storz & Bickel (vaporizers). During the period, the company executed significant capital restructuring, including the completion of ATM equity programs and the repayment of its Credit Facility.
Key Financial Metrics
| Metric (CDN$ in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Revenue | 74,541 | 74,761 | 213,358 | 203,964 |
| Gross Margin | 21,466 | 24,098 | 61,409 | 68,967 |
| Gross Margin % | 29% | 32% | 29% | 34% |
| Operating Loss | (26,350) | (23,822) | (65,868) | (98,873) |
| Net Loss (Continuing Ops) | (62,627) | (121,896) | (105,793) | (382,637) |
| Loss Per Share (Diluted) | (0.18) | (1.11) | (0.39) | (4.15) |
| Cash & Equivalents (End of Period) | 371,322 | - | 371,322 | - |
| Total Debt (Long-term) | 224,989 | - | 224,989 | - |
Note: Balance sheet figures for debt and cash are as of December 31, 2025. Comparative balance sheet data for Q3 2024 is not explicitly provided in the text, though 9M cash flow data is available.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss from continuing operations improved significantly year-over-year. For the nine months ended Dec 31, 2025, the loss was $105.8 million compared to $382.6 million in the prior year. This improvement was driven primarily by a $237.9 million reduction in "Other income (expense), net," largely due to decreased non-cash fair value losses on Canopy USA-related assets.
- Revenue Stability: Net revenue remained relatively flat quarter-over-quarter ($74.5M vs $74.8M) but grew 5% year-over-year for the nine-month period ($213.4M vs $204.0M). Growth was led by Canadian adult-use (+26%) and medical cannabis (+15%), offset by declines in International markets (-22%) and Storz & Bickel (-14%).
- Margin Compression: Gross margin percentage declined to 29% (Q3) and 29% (9M) from 32% and 34% respectively in the prior year. This was attributed to lower international sales, higher inventory provisions, and increased tariffs on U.S. imports.
- Operating Expenses: Total operating expenses decreased by 24% year-over-year for the nine-month period ($127.3M vs $167.8M), driven by a significant reduction in share-based compensation ($2.8M vs $14.5M) and lower impairment/restructuring costs ($5.6M vs $22.1M).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management highlighted cost-saving initiatives, including headcount reductions and lower third-party costs, which contributed to improved Adjusted EBITDA (loss narrowed to $13.8M for 9M 2025 from $14.3M in 2024). The company is focused on deleveraging and optimizing its capital structure.
Subsequent Events (Post-Dec 31, 2025)
- MTL Cannabis Acquisition: Entered into an agreement to acquire MTL Cannabis Corp. (subject to shareholder and regulatory approval).
- Debt Refinancing: On January 8, 2026, the company entered a new Loan Agreement for a senior secured term loan of approximately US$162.1 million (US$150M cash advanced). Proceeds were used to repay the outstanding Credit Facility in full.
- Debt Exchange: Exchanged the May 2024 Convertible Debenture for new January 2026 Convertible Debentures ($55M principal), warrants, and common shares.
Risks and Contingencies
- Acreage/Wana Debt Default: Acreage is currently in default under the Third ARCA. The debt owed to the ARCA Lender ranks in priority to the debt owed to Canopy Growth. If Acreage or Wana cannot satisfy obligations, Canopy Growth may lose its entire investment in these debts, negatively impacting its U.S. strategy.
- Regulatory Risks: The proposed 2025 Canadian federal budget suggests reducing medical cannabis reimbursement rates for RCMP and Veterans Affairs, which could materially decline medical cannabis revenues and margins.
- Legal Proceedings: The company is subject to ongoing SEC investigations regarding the BioSteel Review and multiple putative class actions in Canada and the U.S. regarding financial disclosures.
Investor Verification Checklist
- Debt Structure: Verify the terms and covenants of the new January 2026 Loan Agreement and Convertible Debentures, specifically interest rates, maturity dates, and prepayment penalties.
- Acreage Solvency: Monitor the status of Acreage's default under the Third ARCA and the likelihood of recovery on the $166.5 million (CDN) debt owed to Canopy Growth.
- MTL Acquisition: Track the progress of the MTL Cannabis acquisition, including shareholder vote results (scheduled Feb 17, 2026) and regulatory approvals.
- Medical Cannabis Policy: Assess the final impact of the Canadian 2025 Budget on medical cannabis reimbursement rates and the company's pricing strategy.
- Legal Exposure: Review updates on the SEC investigation regarding BioSteel and the status of the certified class action in Ontario (Dziedziejko).